Histamine H<sub>4</sub> receptor antagonism reduces hapten‐induced scratching behaviour but not inflammation
Kristine Roßbach(University of Veterinary Medicine Hannover, Foundation), Wolfgang Bäumer(Freie Universität Berlin), Stephanie Wendorff(University of Veterinary Medicine Hannover, Foundation), Thomas Werfel(Medizinische Hochschule Hannover), Manfred Kietzmann(University of Veterinary Medicine Hannover, Foundation), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Holger Stark(Heinrich Heine University Düsseldorf), Kerstin Sander(Goethe University Frankfurt)
Cited by 127
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
|Pharmacological Reviews|2015|558